390
Participants
Start Date
December 13, 2021
Primary Completion Date
April 26, 2023
Study Completion Date
February 21, 2024
Amlitelimab
Pharmaceutical form: Injection solution Route of administration: Subcutaneous
Placebo
Pharmaceutical form: Injection solution Route of administration: Subcutaneous
Investigative Site Number: 3202, Taichung
Investigative Site Number: 3201, Niao Song Qu
Investigative Site Number: 2304, Budapest
Investigative Site Number: 2005, Sofia
Investigative Site Number: 2006, Sofia
Investigative Site Number: 2003, Sofia
Investigative Site Number: 2002, Sofia
Investigative Site Number: 2208, Kiel
Investigative Site Number: 3003, East Melbourne
Investigative Site Number: 2505, Alicante
Investigational Site Number: 3001, Parkville
Investigative Site Number 3002, Carlton
Investigative Site Number: 2303, Debrecen
Investigative Site Number: 2306, Szolnok
Investigative Site Number: 2305, Gyula
Investigative Site Number: 2004, Pleven
Investigative Site Number: 2307, Kecskemét
Investigative Site Number: 2001, Stara Zagora
Investigative Site Number: 2301, Szeged
Investigative Site Number: 2302, Zalaegerszeg
Investigative Site Number: 2203, Berlin
Investigative site # 3206, Taipei
Investigative Site Number: 2501, Córdoba
Investigative Site Number: 2202, Blankenfelde
Investigative Site Number: 2204, Hamburg
Investigative Site Number: 2503, Madrid
Investigative Site Number: 3203, Taoyuan District
Investigative Site Number: 1006, Boca Raton
Investigative Site Number: 2504, Pontevedra
Investigative Site Number: 1021, Louisville
Investigative Site Number: 2502, Manises
Investigator Site Number: 2201, Münster
Investigative site #1023, Mansfield
Investigative Site Number: 2209, Erlangen
Investigative Site Number: 1009, Portland
Investigative site # 3206, Taipei
Investigative Site Number: 1018, Fremont
Investigative site #1022, Sacramento
Investigative Site Number: 1001, Clearwater
Investigative Site Number: 1019, Coral Gables
Investigative Site Number: 1007, Miami
Investigative Site Number: 1013, Tampa
Investigative Site Number: 1004, Savannah
Investigative Site Number: 1010, Clarksville
Investigative Site Number: 1015, Indianapolis
Investigative Site Number: 1011, Towson
Investigative Site Number: 1014, Beverly
Investigative Site Number: 1012, Troy
Investigative Site Number: 1005, Tulsa
Investigative Site Number: 1017, Portland
Investigative Site Number: 1003, Anderson
Investigative Site Number: 1008, Murfreesboro
Investigative Site Number: 1106, Markham
Investigative site #1108, Niagara Falls
Investigative Site Number: 1103, Ottawa
Investigative Site Number: 1107, Waterloo
Investigative Site Number: 1101, Windsor
Investigative Site Number: 2105, Nový Jicín
Investigative Site Number: 2102, Prague
Investigative Site Number: 2103, Prague
Investigative Site Number: 2108, Brno
Investigative Site Number: 2106, Kutná Hora
Investigative Site Number: 2104, Ostrava
Investigative Site Number: 3103, Matsudo
Investigative Site Number: 3114, Obihiro-Shi
Investigative site #3108, Kagoshima
Investigative site #3113, Yokohama
Investigative Site Number: 3112, Adachi-Ku
Investigative Site Number: 3115, Chuo Ku
Investigative Site Number: 3104, Edagowa-Ku
Investigative Site Number: 3111, Koto-Ku
Investigative Site Number: 3107, Minato-Ku
Investigative site #3105, Setagaya-Ku
Investigative site #3102, Kyoto
Investigative Site Number: 3106, Mibu-machi
Investigative site #3101, Sapporo
Investigative Site Number: 3109, Habikino-Shi
Investigative Site Number: 3110, Sakaishi
Investigative Site Number: 2408, Krakow
Investigative Site Number: 2407, Krakow
Investigative Site Number: 2409, Krakow
Investigative Site Number: 2414, Wroclaw
Investigative Site Number: 2418, Wroclaw
Investigative Site Number: 2417, Wroclaw
Investigative Site Number: 2420, Lodz
Investigative site #2420, Lodz
Investigative Site Number: 2415, Lódz
Investigative Site Number: 2412, Warsaw
Investigative Site Number: 2411, Warsaw
Investigative Site Number: 2413, Warsaw
Investigative Site Number: 2401, Rzeszów
Investigative site #2419, Bialystok
Investigative site #2419, Bialystok
Investigative Site Number: 2402, Gdansk
Investigative Site Number: 2404, Gdynia
Investigative Site Number: 2405, Katowice
Investigative Site Number: 2410, Szczecin
Investigative Site Number: 2403, Gdansk
Investigative Site Number: 2406, Krakow
Investigative Site Number: 2416, Lodz
Investigative Site Number: 2603, London
Investigative Site Number: 2601, London
Investigative Site Number: 2602, Sheffield
Collaborators (1)
Sanofi
INDUSTRY
Kymab Limited
INDUSTRY